Charles Schwab’s BioVie BIVI Stock Holding History

Charles Schwab’s Portfolio BIVI Stock Details BIVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-299	Closed	-$15.8K	–	3629
2024 Q1	$15.8K	Hold	299	–	–	﹤0.01%	3443
2023 Q4	$37.7K	Buy	299 +183	+158%	+$55K	﹤0.01%	3431
2023 Q3	$39.6K	Hold	116	–	–	﹤0.01%	3426
2023 Q2	$50K	Buy	+116	New	+$78.2K	﹤0.01%	3422

Other funds holding BIVI

ACM

Altium Capital Management New York $42M AUM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Charles Schwab's BIVI Position: Q2 2024 in Review

Charles Schwab sold out of BioVie (BIVI) in Q2 2024, closing a stake of 299 shares — an estimated $15.8K sold.

Charles Schwab first reported a position in BIVI in Q2 2023 and held it in 4 quarters. The position peaked at $50K in Q2 2023. 48 funds tracked by Wall St. Rank hold BIVI as of Q2 2024.

Charles Schwab reported no remaining BioVie position as of Q2 2024 after selling out during the quarter.
Charles Schwab sold 299 BioVie shares in Q2 2024, an estimated $15.8K.
Charles Schwab first reported a position in BioVie in Q2 2023 and held it in 4 quarters.
Charles Schwab's BioVie position peaked at $50K in Q2 2023.
48 funds tracked by Wall St. Rank held BioVie as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.